[go: up one dir, main page]

FI921222A0 - Aminoguanidiner. - Google Patents

Aminoguanidiner.

Info

Publication number
FI921222A0
FI921222A0 FI921222A FI921222A FI921222A0 FI 921222 A0 FI921222 A0 FI 921222A0 FI 921222 A FI921222 A FI 921222A FI 921222 A FI921222 A FI 921222A FI 921222 A0 FI921222 A0 FI 921222A0
Authority
FI
Finland
Prior art keywords
optionally substituted
heterocyclic radical
alkyl
aza
carbamoyl
Prior art date
Application number
FI921222A
Other languages
English (en)
Other versions
FI102371B (fi
FI921222A7 (fi
FI102371B1 (fi
Inventor
Rudolf Karl Andreas Giger
Henri Mattes
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI921222(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919106179A external-priority patent/GB9106179D0/en
Priority claimed from GB919107927A external-priority patent/GB9107927D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Priority to FI971545A priority Critical patent/FI971545A0/fi
Publication of FI921222A0 publication Critical patent/FI921222A0/fi
Publication of FI921222A7 publication Critical patent/FI921222A7/fi
Application granted granted Critical
Publication of FI102371B publication Critical patent/FI102371B/fi
Publication of FI102371B1 publication Critical patent/FI102371B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
FI921222A 1991-03-22 1992-03-20 Menetelmä indol-3-yyli-amino-guanidiiniyhdisteiden valmistamiseksi FI102371B1 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI971545A FI971545A0 (fi) 1991-03-22 1992-03-20 Aminoguanidineja

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9106179 1991-03-22
GB919106179A GB9106179D0 (en) 1991-03-22 1991-03-22 Improvements in or relating to organic compounds
GB9107927 1991-04-15
GB919107927A GB9107927D0 (en) 1991-04-15 1991-04-15 Improvements in or relating to organic compounds

Publications (4)

Publication Number Publication Date
FI921222A0 true FI921222A0 (fi) 1992-03-20
FI921222A7 FI921222A7 (fi) 1992-09-23
FI102371B FI102371B (fi) 1998-11-30
FI102371B1 FI102371B1 (fi) 1998-11-30

Family

ID=26298625

Family Applications (2)

Application Number Title Priority Date Filing Date
FI921222A FI102371B1 (fi) 1991-03-22 1992-03-20 Menetelmä indol-3-yyli-amino-guanidiiniyhdisteiden valmistamiseksi
FI20010060A FI20010060L (fi) 1991-03-22 2001-01-11 5-metoksi-indoli-3-karboksialdehydiamino-(pentyyliamino)metyleeni-hydratsoni

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20010060A FI20010060L (fi) 1991-03-22 2001-01-11 5-metoksi-indoli-3-karboksialdehydiamino-(pentyyliamino)metyleeni-hydratsoni

Country Status (22)

Country Link
US (1) US5510353A (fi)
EP (1) EP0505322B1 (fi)
JP (1) JP2593022B2 (fi)
KR (1) KR100198018B1 (fi)
AT (1) ATE170838T1 (fi)
AU (1) AU651442B2 (fi)
CA (1) CA2063671C (fi)
CZ (1) CZ284339B6 (fi)
DE (1) DE69226894T2 (fi)
DK (1) DK0505322T3 (fi)
ES (1) ES2121836T3 (fi)
FI (2) FI102371B1 (fi)
HU (2) HUT64023A (fi)
IE (1) IE920895A1 (fi)
IL (1) IL101312A (fi)
MX (1) MX9201244A (fi)
MY (1) MY108158A (fi)
NO (1) NO179171C (fi)
NZ (1) NZ242069A (fi)
RO (1) RO109194B1 (fi)
SG (1) SG43221A1 (fi)
SK (1) SK279214B6 (fi)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763459A (en) * 1992-05-23 1998-06-09 Smithkline Beecham P.L.C. Medicaments for the treatment of anxiety
WO1994000113A2 (en) * 1992-06-27 1994-01-06 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
JP3035818B2 (ja) * 1997-10-21 2000-04-24 日本精工株式会社 玉軸受
EP0991097B1 (en) 1998-04-16 2009-11-25 Toshiba Lighting & Technology Corporation Electrical high-pressure discharge lamp and lighting device
IT1314185B1 (it) * 1998-08-21 2002-12-06 Novartis Ag Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
RU2260424C9 (ru) * 1998-08-21 2006-05-20 Новартис Аг Новая композиция для перорального введения
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
KR100901683B1 (ko) 2001-08-10 2009-06-08 닛뽕 케미파 가부시키가이샤 퍼옥시좀 증식제 응답성 수용체 δ의 활성화제
ATE434616T1 (de) 2001-10-12 2009-07-15 Nippon Chemiphar Co Aktivator des peroxisomproliferator-aktivierten rezeptors delta
AU2003209114A1 (en) * 2002-02-14 2003-09-04 Wyeth Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6951881B2 (en) 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6906095B2 (en) 2002-05-10 2005-06-14 Wyeth Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2353383C2 (ru) 2003-01-28 2009-04-27 Айронвуд Фармасьютикалз, Инк. Способы и композиции для лечения желудочно-кишечных расстройств
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
US20050165085A1 (en) * 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
WO2005105740A2 (en) * 2004-04-26 2005-11-10 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod and tegaserod maleate
WO2006002212A1 (en) * 2004-06-23 2006-01-05 Dr. Reddy's Laboratories Ltd. Tegaserod hemimaleate
US20060128788A1 (en) * 2004-10-19 2006-06-15 Santiago Ini Purification of tegaserod maleate
US20080161307A1 (en) * 2005-01-31 2008-07-03 David Lewis Earnest Organic Compounds
WO2006116953A1 (en) * 2005-05-02 2006-11-09 Zentiva, A.S. A method for the preparation of tegaserod and slected salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
EP1947097A1 (en) * 2005-10-27 2008-07-23 Teijin Pharma Limited BENZOÝb¨THIOPHEN DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
GB0601953D0 (en) * 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ZA200809148B (en) 2006-04-18 2010-01-27 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta
CN100412059C (zh) * 2006-06-06 2008-08-20 江苏奥赛康药业有限公司 一种替加色罗的制备方法
EP2086931A1 (en) * 2006-11-09 2009-08-12 Merck Generics (UK) Limited Novel process
EP1939176A1 (en) * 2006-12-22 2008-07-02 Novartis AG Salts of Tegaserod
WO2008149139A2 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod fumarate and polymorphic forms
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2008149140A2 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod oxalate and polymorphic forms
WO2008149138A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod malate and polymorphic forms
WO2008149136A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegaserod besylate and polymorphic forms
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008149137A2 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Tegazerod benzoate and polymorphic forms
WO2008149154A2 (en) * 2007-06-05 2008-12-11 Generics [Uk] Limited Tegaserod succinate and polymorphic forms
US20090082419A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched tegaserod
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
PL2277874T3 (pl) 2008-04-15 2018-11-30 Nippon Chemiphar Co., Ltd. Aktywator receptora aktywowanego przez proliferatory peroksysomów
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100179225A1 (en) * 2008-09-19 2010-07-15 Cytokine Pharmasciences, Inc. POI Prevention
JP6265583B2 (ja) 2008-10-17 2018-01-24 ウィスコンシン アルムニ リサーチ ファンデイション 生理活性アルファベータペプチドを作製する方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PL2384318T3 (pl) 2008-12-31 2018-04-30 Ardelyx, Inc. Związki i sposoby inhibicji mediowanego przez NHE antyportu w leczeniu zaburzeń związanych z retencją płynów lub nadmiarem soli i chorób przewodu pokarmowego
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
ES2534226T3 (es) 2009-09-03 2015-04-20 Bioenergenix Compuestos heterocíclicos para la inhibición de PASK
IN2012DN02471A (fi) 2009-10-09 2015-08-21 Irm Llc
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
MX337477B (es) 2011-02-25 2016-03-07 Yuhan Corp Derivados de diaminopiridina y procesos para su preparacion.
EP2681207B1 (en) 2011-03-02 2016-12-28 Bioenergenix Heterocyclic compounds for the inhibition of pask
CA2880639A1 (en) 2012-08-01 2014-02-06 The Hospital For Sick Children Inhibitors of peptidyl arginine deiminase (pad) enzymes and uses thereof
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
EP2724723A1 (en) 2012-10-25 2014-04-30 Universitätsklinikum Hamburg-Eppendorf Tegaserod for use in the treatment of nerve injuries
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HUE044550T2 (hu) 2013-04-12 2019-11-28 Ardelyx Inc NHE-3 megkötõ vegyületek és foszfát transzport gátlási módszerek
KR101657616B1 (ko) 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
CN103467358B (zh) * 2013-08-15 2015-09-02 蚌埠丰原医药科技发展有限公司 马来酸替加色罗的制备方法
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
US11242337B2 (en) 2017-01-09 2022-02-08 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
US10278955B1 (en) * 2017-12-13 2019-05-07 Macau University Of Science And Technology Methods of treating cancer
TWI833113B (zh) * 2020-09-28 2024-02-21 日商日本精工股份有限公司 斜角滾珠軸承
CN112979528B (zh) * 2021-02-01 2023-02-28 青岛海洋生物医药研究院 一种替加色罗水溶性有机酸盐及其制备方法与应用
CN113845464B (zh) * 2021-10-28 2023-05-02 西安交通大学 一种吲哚胍类化合物及其制备方法和应用
CN113801052B (zh) * 2021-10-28 2023-06-27 西安交通大学 一种含有芳香酸酯的吲哚胍类化合物及其制备方法和应用
WO2023242102A1 (en) 2022-06-13 2023-12-21 KHR Biotec GmbH Novel ras inhibitors
CN120112537A (zh) * 2022-10-27 2025-06-06 勤浩医药（苏州）有限公司 含磷化合物、药物组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB842324A (en) * 1956-10-01 1960-07-27 Ici Ltd Aminoguanidine derivatives
GB842323A (en) * 1956-10-01 1960-07-27 Ici Ltd Aminoguanidine derivatives
GB842325A (en) * 1956-10-01 1960-07-27 Ici Ltd Pharmaceutical compositions containing aminoguanidine derivatives
GB842322A (en) * 1956-10-01 1960-07-27 Ici Ltd Aminoguanidine derivatives
US2855398A (en) * 1956-11-19 1958-10-07 Searle & Co Amidines of the indole series
US3317560A (en) * 1963-01-03 1967-05-02 Philips Corp Indol-3-yl alkylguanidine derivatives
DE3360148D1 (en) * 1982-02-10 1985-06-05 Beecham Group Plc Guanidine derivatives
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
CS85892A3 (en) 1992-10-14
JPH0586026A (ja) 1993-04-06
NZ242069A (en) 1995-02-24
DE69226894D1 (de) 1998-10-15
EP0505322B1 (en) 1998-09-09
MX9201244A (es) 1993-01-01
EP0505322A1 (en) 1992-09-23
ES2121836T3 (es) 1998-12-16
HU9200761D0 (en) 1992-05-28
CZ284339B6 (cs) 1998-10-14
HU211510A9 (en) 1995-11-28
FI20010060A7 (fi) 2001-01-11
JP2593022B2 (ja) 1997-03-19
SK279214B6 (sk) 1998-08-05
KR100198018B1 (ko) 1999-06-15
IL101312A (en) 1997-03-18
FI102371B (fi) 1998-11-30
IL101312A0 (en) 1992-11-15
AU1309292A (en) 1992-09-24
FI921222A7 (fi) 1992-09-23
US5510353A (en) 1996-04-23
FI102371B1 (fi) 1998-11-30
KR920018055A (ko) 1992-10-21
DK0505322T3 (da) 1999-06-07
FI20010060L (fi) 2001-01-11
AU651442B2 (en) 1994-07-21
ATE170838T1 (de) 1998-09-15
HK1011028A1 (en) 1999-07-02
CA2063671C (en) 2005-03-15
NO179171B (no) 1996-05-13
HUT64023A (en) 1993-11-29
DE69226894T2 (de) 1999-02-18
NO921104L (no) 1992-09-23
IE920895A1 (en) 1992-09-23
NO179171C (no) 1996-08-21
MY108158A (en) 1996-08-30
SG43221A1 (en) 1997-10-17
RO109194B1 (ro) 1994-12-30
CA2063671A1 (en) 1992-09-23
NO921104D0 (no) 1992-03-20

Similar Documents

Publication Publication Date Title
FI921222A0 (fi) Aminoguanidiner.
ATE334974T1 (de) Aminotetrazolderivate als stickstoffmonoxid- synthaseinhibitoren
DE3876813D1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
GB2248616B (en) Piperazine derivatives
DK165247C (da) 2,3,4,5-substituerede 1,6-naphthyridinderivater, deres fremstilling samt anvendelse af disse til fremstilling af laegemidler til bekaempelse af cardiale, cerebrale og perifere karlidelser, myocardial iskaemi, cerebral infarkt, lungethrombose, stenoser, arterioscleroser og hjerte-kredsloebslidelser og laegemiddel indeholdende disse derivater
GR3017065T3 (en) Disubstituted ureas and thioureas.
GB2254324B (en) Piperazine derivatives
AU597923B2 (en) 5-aminoalkyl-beta-carboline derivatives, their production and their use as drugs

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

MA Patent expired